Trevena Inc (NASDAQ:TRVN) Expected to Announce Earnings of -$0.08 Per Share

Share on StockTwits

Brokerages expect Trevena Inc (NASDAQ:TRVN) to post earnings per share of ($0.08) for the current quarter, according to Zacks. Zero analysts have provided estimates for Trevena’s earnings. Trevena reported earnings per share of ($0.06) during the same quarter last year, which suggests a negative year over year growth rate of 33.3%. The firm is expected to announce its next quarterly earnings results on Thursday, November 14th.

According to Zacks, analysts expect that Trevena will report full year earnings of ($0.27) per share for the current fiscal year. For the next year, analysts expect that the firm will report earnings of ($0.33) per share. Zacks Investment Research’s EPS averages are a mean average based on a survey of research firms that cover Trevena.

Trevena (NASDAQ:TRVN) last posted its earnings results on Wednesday, August 7th. The biopharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.05.

A number of research analysts have recently issued reports on TRVN shares. Zacks Investment Research upgraded shares of Trevena from a “hold” rating to a “buy” rating and set a $1.00 target price for the company in a research note on Tuesday, August 13th. ValuEngine upgraded shares of Trevena from a “sell” rating to a “hold” rating in a research note on Thursday, August 1st. Finally, HC Wainwright set a $4.00 price objective on shares of Trevena and gave the stock a “buy” rating in a research report on Monday, June 24th. Three research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. Trevena presently has an average rating of “Buy” and an average price target of $5.25.

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Two Sigma Advisers LP grew its holdings in shares of Trevena by 35.3% in the 4th quarter. Two Sigma Advisers LP now owns 62,900 shares of the biopharmaceutical company’s stock valued at $27,000 after buying an additional 16,400 shares during the period. Alpine Global Management LLC acquired a new position in shares of Trevena in the 1st quarter valued at $31,000. Geode Capital Management LLC grew its holdings in shares of Trevena by 38.9% in the 4th quarter. Geode Capital Management LLC now owns 477,007 shares of the biopharmaceutical company’s stock valued at $205,000 after buying an additional 133,510 shares during the period. Vanguard Group Inc. grew its holdings in shares of Trevena by 11.5% in the 2nd quarter. Vanguard Group Inc. now owns 3,915,315 shares of the biopharmaceutical company’s stock valued at $4,032,000 after buying an additional 403,060 shares during the period. Finally, BlackRock Inc. grew its holdings in shares of Trevena by 1.9% in the 2nd quarter. BlackRock Inc. now owns 2,647,830 shares of the biopharmaceutical company’s stock valued at $2,727,000 after buying an additional 49,900 shares during the period. 22.88% of the stock is owned by hedge funds and other institutional investors.

NASDAQ:TRVN opened at $0.89 on Friday. Trevena has a 1 year low of $0.38 and a 1 year high of $3.58. The firm has a 50 day moving average of $0.95 and a 200-day moving average of $1.27. The company has a current ratio of 3.77, a quick ratio of 3.77 and a debt-to-equity ratio of 0.19.

Trevena Company Profile

Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of treatment options that target and treat diseases affecting the central nervous system. Its product candidates include Oliceridine injection, a G protein biased mu-opioid receptor (MOR) ligand that has completed Phase III clinical trials for the management of moderate-to-severe acute pain where intravenous administration is warranted; TRV250, a G protein biased delta- opioid receptor ligand, which is in Phase I clinical study for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR that has completed Phase I clinical study for the treatment of moderate-to-severe acute and chronic pain; TRV027 for the treatment of acute heart failure; and TRV045, a novel S1P modulator for managing chronic pain.

Further Reading: The Discount Rate – What You Need to Know

Get a free copy of the Zacks research report on Trevena (TRVN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Trevena (NASDAQ:TRVN)

Receive News & Ratings for Trevena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevena and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Stryker Co.  Shares Bought by Connors Investor Services Inc.
Stryker Co. Shares Bought by Connors Investor Services Inc.
Connors Investor Services Inc. Has $50.94 Million Holdings in SPDR S&P 500 ETF Trust
Connors Investor Services Inc. Has $50.94 Million Holdings in SPDR S&P 500 ETF Trust
Connors Investor Services Inc. Acquires 3,370 Shares of Nike Inc
Connors Investor Services Inc. Acquires 3,370 Shares of Nike Inc
Fortress Investment Group LLC Acquires Shares of 158,313 LYFT Inc
Fortress Investment Group LLC Acquires Shares of 158,313 LYFT Inc
Clearline Capital LP Purchases Shares of 235,869 Change Healthcare Inc.
Clearline Capital LP Purchases Shares of 235,869 Change Healthcare Inc.
37,258 Shares in Theravance Biopharma Inc  Bought by Clearline Capital LP
37,258 Shares in Theravance Biopharma Inc Bought by Clearline Capital LP


© 2006-2019 Ticker Report